Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism

PURPOSE OF REVIEW: To present the randomized controlled trial (RCT) evidence and highlight the areas of uncertainty regarding direct oral anticoagulants (DOAC) for cancer-associated venous thromboembolism (CAT). RECENT FINDINGS: In the last years, four RCTs have shown that rivaroxaban, edoxaban, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Masini, Marta, Toma, Matteo, Spallarossa, Paolo, Porto, Italo, Ameri, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474987/
https://www.ncbi.nlm.nih.gov/pubmed/37278934
http://dx.doi.org/10.1007/s11912-023-01428-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474987/
https://www.ncbi.nlm.nih.gov/pubmed/37278934
http://dx.doi.org/10.1007/s11912-023-01428-y

Ejemplares similares